Aytu BioPharma - AYTU Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 87.27%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.67
▼ -0.22 (-7.61%)

This chart shows the closing price for AYTU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aytu BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AYTU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AYTU

Analyst Price Target is $5.00
▲ +87.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Aytu BioPharma in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 87.27% upside from the last price of $2.67.

This chart shows the closing price for AYTU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Aytu BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2023Maxim GroupInitiated CoverageBuy$5.00Low
2/22/2023Cantor FitzgeraldReiterated RatingOverweightLow
7/21/2022HC WainwrightLower TargetBuy$11.00 ➝ $6.00Low
5/17/2022Cantor FitzgeraldLower Target$11.00 ➝ $5.00High
4/28/2022HC WainwrightLower TargetBuy$24.00 ➝ $11.00Low
6/18/2021LADENBURG THALM/SH SHReiterated RatingBuy$14.50High
3/29/2021Cantor FitzgeraldInitiated CoverageOverweight$11.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$3.00Medium
5/29/2020HC WainwrightInitiated CoverageBuy$3.00High
11/15/2019Northland SecuritiesInitiated CoverageBuy$5.00High
9/27/2019Northland SecuritiesSet TargetBuy$10.00Low
9/18/2019LADENBURG THALM/SH SHBoost Target$4.00 ➝ $4.75Medium
9/13/2019Northland SecuritiesSet TargetBuy$10.00Medium
7/30/2019Northland SecuritiesReiterated RatingBuy$10.00High
6/4/2019Northland SecuritiesReiterated RatingBuy$10.00High
5/14/2019Northland SecuritiesReiterated RatingBuy$10.00Medium
(Data available from 4/16/2019 forward)

News Sentiment Rating

-0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/15/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Very Positive

  • No very positive mentions tracked during this time.
Aytu BioPharma logo
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.
Read More

Today's Range

Now: $2.67
Low: $2.65
High: $2.86

50 Day Range

MA: $3.01
Low: $2.53
High: $3.36

52 Week Range

Now: $2.67
Low: $1.38
High: $3.50

Volume

55,660 shs

Average Volume

20,309 shs

Market Capitalization

$14.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aytu BioPharma?

The following sell-side analysts have issued reports on Aytu BioPharma in the last year: Maxim Group.
View the latest analyst ratings for AYTU.

What is the current price target for Aytu BioPharma?

1 Wall Street analysts have set twelve-month price targets for Aytu BioPharma in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 87.3%. Maxim Group has the highest price target set, predicting AYTU will reach $5.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for Aytu BioPharma in the next year.
View the latest price targets for AYTU.

What is the current consensus analyst rating for Aytu BioPharma?

Aytu BioPharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AYTU will outperform the market and that investors should add to their positions of Aytu BioPharma.
View the latest ratings for AYTU.

What other companies compete with Aytu BioPharma?

How do I contact Aytu BioPharma's investor relations team?

Aytu BioPharma's physical mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company's listed phone number is (720) 437-6580 and its investor relations email address is [email protected]. The official website for Aytu BioPharma is aytubio.com. Learn More about contacing Aytu BioPharma investor relations.